Keyphrases
Pancreatic Cancer
100%
Pancreatic Ductal Adenocarcinoma
75%
Tumor
36%
Overall Survival
27%
Germ Cells
25%
Pembrolizumab
23%
Pancreatic Adenocarcinoma
21%
Monotherapy
21%
Advanced Solid Tumors
20%
Breast Cancer Susceptibility Gene 1 (BRCA1)
20%
Germline BRCA
18%
Chemotherapy
18%
Olaparib
17%
Previously Treated
17%
BRCA mutation Carriers
17%
BRCA1, BRCA2
16%
Phase II Trial
15%
Metastatic Pancreatic Cancer
15%
Confidence Interval
15%
Homologous Recombination Deficiency
14%
PARP Inhibitor (PARPi)
14%
BRCA mutation
13%
Combination Therapy
13%
BRCA2 mutation
13%
Cancer Cells
12%
Median Overall Survival
12%
Cancer Patients
11%
Germline BRCA mutation
11%
Radiosurgery
11%
Clinical Characteristics
11%
Adjuvant Chemotherapy
11%
Clinically Significant
11%
Objective Response Rate
10%
Metastatic Colorectal Cancer (mCRC)
10%
Clinical Trials
10%
Placebo
10%
Gemcitabine
9%
Hazard Ratio
9%
Germline mutation
9%
Programmed Death-ligand 1 (PD-L1)
9%
First-in-human
9%
Patient-derived Xenograft
9%
Melanoma
9%
Xenograft
9%
BRCA2
9%
Melanoma Cells
8%
Veliparib
8%
Celiac Plexus
8%
Survival Characteristics
8%
Early Cancer Detection
8%
Medicine and Dentistry
Pancreas Cancer
99%
Pancreas Adenocarcinoma
65%
Germ Cell
40%
Neoplasm
36%
Overall Survival
31%
Malignant Neoplasm
29%
Diseases
26%
BRCA1
24%
BRCA Mutation
21%
Clinical Trial
16%
Olaparib
16%
Arm
15%
Cancer Cell
15%
DNA Repair
15%
Metastatic Carcinoma
13%
Xenograft
13%
BRCA2
13%
Biological Marker
12%
Pembrolizumab
11%
Adjuvant Chemotherapy
10%
Placebo
10%
Personalized Medicine
10%
Adenocarcinoma
10%
Oncology
9%
Gastroesophageal Junction
9%
Hazard Ratio
9%
Adverse Event
9%
Pancreatic Ductal Adenocarcinoma
8%
Disease Exacerbation
8%
Cancer
8%
Radiosurgery
8%
Stomach Adenocarcinoma
8%
Veliparib
8%
Celiac Plexus
8%
Progression Free Survival
8%
Melanoma
7%
Gene Mutation
7%
Colorectal Carcinoma
7%
Immunotherapy
7%
Melanoma Cell
7%
PARP Inhibitor
6%
Abdominal Cancer
6%
Monotherapy
6%
Magnetic Resonance Imaging
6%
Cancer Associated Fibroblast
6%
Ex Vivo
6%
Retrospective Study
6%
Primary Tumor
6%
Poly ADP Ribose Polymerase
6%
Phase II Trials
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
67%
Pancreas Adenocarcinoma
46%
Neoplasm
42%
Overall Survival
32%
Chemotherapy
30%
Diseases
29%
Malignant Neoplasm
26%
Pembrolizumab
26%
Solid Malignant Neoplasm
25%
Monotherapy
21%
Adverse Event
16%
Colorectal Carcinoma
15%
Combination Therapy
15%
Olaparib
15%
Adenocarcinoma
13%
Clinical Trial
12%
Metastatic Colorectal Cancer
11%
Placebo
10%
Colon Carcinoma
10%
Gemcitabine
9%
Abdominal Cancer
9%
Progression Free Survival
9%
Biological Marker
8%
Veliparib
8%
Disease Exacerbation
8%
Antitumor Activity
8%
Phase II Trials
8%
Oxaliplatin
7%
Cisplatin
6%
Retrospective Study
6%
Small Interfering RNA
6%
Pharmacokinetics
6%
Mammalian Target of Rapamycin Inhibitor
5%
Nivolumab
5%
Somatomedin
5%
Fibrinogen
5%
Receptor Antibody
5%
Prodrug
5%
Abemaciclib
5%
Mitomycin
5%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
5%
Non Small Cell Lung Cancer
5%
